ClinicalTrials.gg
CompletedNCT04092686Updated Jun 18, 2026Results posted

A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia

A Phase 3 interventional study of SEP-363856 75mg and SEP-363856 100mg in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 53 sites in 7 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
464
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing SEP-363856 in Schizophrenia — 1 open to participants now, 2 under way, 2 of them phase 3. SEP-363856 · Schizophrenia.

Enrollment
2nd of 23
464 · median 83
Started
2019
with 4 others
Phase 3
9 of 23
1 open now
Registered
8th of 23
by date
Lead sponsor
18 of 23
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 23 studies testing SEP-363856 in Schizophrenia, this one is the 2nd largest by enrollment, is one of 5 that started in 2019, is one of 9 in phase 3, and was the 8th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 23 studies testing SEP-363856 in Schizophrenia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About SEP-363856

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing SEP-363856 in Schizophrenia, or all of them as a file.
02

Study summary

A clinical trial to study the efficacy and safety of an investigational drug in acutely psychotic people with schizophrenia. Participants in the study will either receive the drug being studied or a placebo. This study is accepting male and female participants between 18 -65 years old who have been diagnosed with schizophrenia. This study will be conducted in 60 locations world wide. The study will last up to nine (9) weeks.

Read the detailed description

This is a multicenter, randomized, double-blind, parallel-group, fixed-dosed study evaluating the efficacy and safety of two doses of SEP-363856 (75 and 100 mg/day) versus placebo over a 6-week Treatment Period in acutely psychotic participants with schizophrenia. This study is projected to randomize approximately 462 participants to 3 treatment groups (SEP-363856 75 mg/day, SEP-363856 100 mg/day, or placebo) in a 1:1:1 ratio. Treatment assignment will be stratified by country. Study drug will be taken once a day and may be taken with or without food.

This study is designed to test the hypotheses that treatment with SEP-363856 in adult participants with schizophrenia will result in significantly greater reduction (i.e. improvement) in PANSS total score and CGI-S score at Week 6 from Baseline when compared to placebo. The overall Type I error is controlled for two hierarchical families of hypotheses. The first family includes hypotheses about the testing of change from Baseline in PANSS total score at Week 6 between each of the SEP-363856 dose levels vs. placebo. The second family of hypotheses are about the testing of change from Baseline in CGI-S score at Week 6 between each of the SEP-363856 dose levels vs. placebo.

Sumitomo Pharma America Inc. was the former Sponsor and conducted this study. Sumitomo was responsible for analysis and clinical study report (CSR) completion. Otsuka took over study after IND was transferred and is concluding activities with registry postings.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • acute psychosis
  • Schizophrenia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participant between 18 to 65 years of age (inclusive) at the time of consent.
  2. Participant must give written and privacy authorization prior to participation in the study.
  3. Participant meets the Diagnostic and Statistical Manual of Mental Illnesses ( )criteria for schizophrenia as established by clinical interview at screeing.
  4. Participant must have a Clinical Global Impression - Severity (CGI-S) score ≥ 4.
  5. Participant must have a Positive and Negative Syndrome Scale (PANSS) total score ≥ 80 and a PANSS item score ≥ 4 on 2 or more of the following PANSS items: delusions, conceptual disorganization, hallucinations, and unusual thought content.
  6. Participant has an acute exacerbation of psychotic symptoms (persisting no longer than 2 months prior to providing informed consent).
  7. Participant has marked deterioration of functioning in one or more areas.
  8. Participant is, in the opinion of the Investigator, generally healthy based on screening medical history, physical examination (PE), neurological examination, vital signs, (ECG) and clinical laboratory values.

Exclusion criteria

Exclusion Criteria:

  1. Participant has a diagnosis or presence of symptoms consistent with a DSM-5 diagnosis other than schizophrenia. Exclusionary disorders include but are not limited to alcohol use disorder (within past 12 months), substance (other than nicotine or caffeine) use disorder within past 12 months, or lifetime history of significant substance abuse that, in the opinion of the Investigator or Sponsor, may have had a significant and potentially permanent impact on the brain or other body systems, major depressive disorder, bipolar I or II disorder, schizoaffective disorder, obsessive compulsive disorder, and posttraumatic stress disorder. Symptoms of mild to moderate mood dysphoria or anxiety are allowed so long as these symptoms are not the primary focus of treatment.
  2. Participant is at significant risk of harming self, others, or objects based on Investigator's judgment.
  3. Participant has any unstable medical condition or any clinically significant chronic disease that in the opinion of the Investigator, would limit the participant's ability to complete and/or participate in the study
  4. Female participant who is pregnant or lactating
  5. Participant has any clinically significant abnormal laboratory value(s) at Screening as determined by investigator.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
464 participants (actual)

Study arms

  • Experimental
    SEP-363856 75mg

    SEP-363856 75mg dosed once daily

    Drug: SEP-363856 75mg

  • Experimental
    SEP-363856 100mg

    SEP-363856 100mg dosed once daily

    Drug: SEP-363856 100mg

  • Placebo comparator
    Placebo

    Placebo dosed once daily

    Drug: Placebo

Interventions

  • SEP-363856 75mg tablet dosed once daily

  • SEP-363856 100mg tablet dosed once daily

  • DrugPlacebo

    Placebo tablet dosed once daily

06

What researchers measure

Primary outcomes

  1. Change From Baseline in PANSS Total Score at Week 6

    PANSS was an interview-based assessment comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). The Positive subscale assessed hallucinations, delusions, and related symptoms; the Negative subscale assessed emotional withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addressed other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1 - 7, where values of 2 and above indicated the presence of progressively more severe symptoms, was used to score each item. Individual items were then summed to determine scores for the 3 subscales, as well as a total score. PANSS total score ranges from: 30-210, where a higher score indicates greater severity. A negative change from baseline indicates improvement.

    Time frame: Baseline, Week 6

Secondary outcomes

  1. Change From Baseline in CGI-S Score at Week 6

    The CGI-S is a single-item clinician-rated assessment of the participant's current illness state on a 7-point scale (score range: 1-7), where a higher score is associated with greater illness severity. A negative change from baseline indicates improvement.

    Time frame: Baseline, Week 6

07

Results

Posted Jun 18, 2026

Participant flow

Participants took part in the study at investigational sites in Bulgaria, Croatia, Latvia, Serbia, Ukraine, Russia, Colombia, and the United States (US) from 14 Oct 2019 to 14 June 2023.

Participant flow — Overall Study
MilestonePlaceboSEP-363856 75mgSEP-363856 100mg
Started155155154
Modified-intent-to-treat population (mitt)155153152
Completed128121116
Not completed273438
Withdrew: Adverse event101419
Withdrew: Lack of efficacy153
Withdrew: Withdrawal by participant141415
Withdrew: Reason not specified211

Outcome measures

PrimaryChange From Baseline in PANSS Total Score at Week 6

PANSS was an interview-based assessment comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). The Positive subscale assessed hallucinations, delusions, and related symptoms; the Negative subscale assessed emotional withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addressed other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1 - 7, where values of 2 and above indicated the presence of progressively more severe symptoms, was used to score each item. Individual items were then summed to determine scores for the 3 subscales, as well as a total score. PANSS total score ranges from: 30-210, where a higher score indicates greater severity. A negative change from baseline indicates improvement.

Time frame:
Baseline, Week 6
Reported as:
Least squares mean · score on a scale
Change From Baseline in PANSS Total Score at Week 6
score on a scalePlaceboSEP-363856 75mgSEP-363856 100mg
Change From Baseline in PANSS Total Score at Week 6-14.3 ± 1.47-16.4 ± 1.49-18.1 ± 1.50
Statistical analysis
  • Placebo vs SEP-363856 75mg · MMRM · p = 0.132 (MMRM method included fixed effects for treatment, visit (as a categorical variable), country, baseline PANSS total score and treatment by visit interaction. P-value is adjusted one-sided calculated by Hochberg-based gatekeeping procedure.) · Least square (ls) mean difference: -2.1 · 95% CI -5.7 to 1.5
  • Placebo vs SEP-363856 100mg · MMRM · p = 0.041 (MMRM method included fixed effects for treatment, visit (as a categorical variable), country, baseline PANSS total score and treatment by visit interaction. P-value is adjusted one-sided calculated by Hochberg-based gatekeeping procedure.) · Ls mean difference: -3.8 · 95% CI -7.5 to -0.1
SecondaryChange From Baseline in CGI-S Score at Week 6

The CGI-S is a single-item clinician-rated assessment of the participant's current illness state on a 7-point scale (score range: 1-7), where a higher score is associated with greater illness severity. A negative change from baseline indicates improvement.

Time frame:
Baseline, Week 6
Reported as:
Least squares mean · score on a scale
Change From Baseline in CGI-S Score at Week 6
score on a scalePlaceboSEP-363856 75mgSEP-363856 100mg
Change From Baseline in CGI-S Score at Week 6-0.78 ± 0.088-0.91 ± 0.089-0.93 ± 0.090
Statistical analysis
  • Placebo vs SEP-363856 75mg · MMRM · p = 0.219 (MMRM method included fixed effects for treatment, visit (as a categorical variable), country, baseline CGI-S score, and treatment by visit interaction.) · Ls mean difference: -0.14 · 95% CI -0.36 to 0.08
  • Placebo vs SEP-363856 100mg · MMRM · p = 0.172 (MMRM method included fixed effects for treatment, visit (as a categorical variable), country, baseline CGI-S score, and treatment by visit interaction.) · Ls mean difference: -0.15 · 95% CI -0.37 to 0.07

Adverse events

Collected over From the first dose of study drug up to 7 days after the last dose of the study drug (up to approximately 7 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/155 (0%)6/155 (3.9%)36/155 (23.2%)
SEP-363856 75mg0/155 (0%)14/155 (9%)53/155 (34.2%)
SEP-363856 100mg0/154 (0%)11/154 (7.1%)52/154 (33.8%)
Most frequent serious events
Most frequent serious events
EventPlaceboSEP-363856 75mgSEP-363856 100mg
SchizophreniaPsychiatric disorders4/15513/1559/154
Corona virus infectionInfections and infestations1/1550/1551/154
Toxicity to various agentsInjury, poisoning and procedural complications0/1550/1551/154
Malignant catatoniaPsychiatric disorders0/1551/1550/154
Food poisoningGastrointestinal disorders0/1551/1550/154
RhabdomyolysisMusculoskeletal and connective tissue disorders0/1551/1550/154
Coronavirus test positiveInvestigations1/1550/1550/154
Most frequent other events
Most frequent other events
EventPlaceboSEP-363856 75mgSEP-363856 100mg
HeadacheNervous system disorders14/15518/15517/154
AnxietyPsychiatric disorders6/15517/15512/154
InsomniaPsychiatric disorders9/15515/15513/154
SchizophreniaPsychiatric disorders7/15511/15513/154
AgitationPsychiatric disorders8/1559/1555/154

Baseline characteristics

The safety population included all participants that were randomized and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)PlaceboSEP-363856 75mgSEP-363856 100mgTotal
Mean38.6 ± 10.8238.5 ± 11.2437.5 ± 10.3338.2 ± 10.79
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboSEP-363856 75mgSEP-363856 100mgTotal
Female657156192
Male908498272
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboSEP-363856 75mgSEP-363856 100mgTotal
Hispanic or Latino614727
Not Hispanic or Latino149141147437
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboSEP-363856 75mgSEP-363856 100mgTotal
American Indian or Alaska Native0000
Asian3014
Native Hawaiian or Other Pacific Islander3137
Black or African American393340112
White108118108334
More than one race0101
Unknown or Not Reported2226
Region of Enrollment
Region of Enrollment(participants)PlaceboSEP-363856 75mgSEP-363856 100mgTotal
Latvia2226
United States495048147
Ukraine21222265
Bulgaria67821
Serbia454444133
Russia29282885
Croatia2013
Colombia1214
Baseline PANSS total score
Baseline PANSS total score(Score on a scale)PlaceboSEP-363856 75mgSEP-363856 100mgTotal
Mean100.2 ± 8.23101.0 ± 10.50100.0 ± 9.28100.4 ± 9.37
Baseline CGI-S score
Baseline CGI-S score(score on a scale)PlaceboSEP-363856 75mgSEP-363856 100mgTotal
Mean5.05 ± 0.4385.02 ± 0.5034.99 ± 0.5185.02 ± 0.487
08

Study locations

53 sites
  • Research Site
    Rogers, Arkansas 72758, United States
  • Research Site
    Anaheim, California 92805, United States
  • Research Site
    Bellflower, California 90706, United States
  • Research Site
    Culver City, California 90230, United States
  • Research Site
    Long Beach, California 90806, United States
  • Research Site
    San Diego, California 92102, United States
  • Research Site
    Sherman Oaks, California 91403, United States
  • Research Site
    Hollywood, Florida 33021, United States
  • Research Site
    Miami Springs, Florida 33166, United States
  • Research Site
    Atlanta, Georgia 30331, United States
  • Research Site
    Decatur, Georgia 30030, United States
  • Research Site
    Chicago, Illinois 60641, United States
  • Research Site
    Lake Charles, Louisiana 70629, United States
  • Research Site
    Gaithersburg, Maryland 20877, United States
  • Research Site
    St Louis, Missouri 63125, United States
  • Research Site
    Marlton, New Jersey 08053, United States
  • Research Site
    New York, New York 10032, United States
  • Research Site
    Richardson, Texas 75080, United States
  • Research Site
    Burgas, 8000, Bulgaria
  • Research Site
    Kardzhali, 6600, Bulgaria
  • Research Site
    Novi Iskar, 1282, Bulgaria
  • Research Site
    Plovdiv, 4000, Bulgaria
  • Research Site
    Sofia, 1202, Bulgaria
  • Research Site
    Sofia, 1431, Bulgaria
  • Research Site
    Zagreb, 10090, Croatia
  • Research Site
    Daugavpils, LV-5417, Latvia
  • Research Site
    Riga, LV-1005, Latvia
  • Research Site
    Strenči, LV-4730, Latvia
  • Research Site
    Arkhangelsk, 163530, Russia
  • Research Site
    Engel's, 413124, Russia
  • Research Site
    Moscow, 117152, Russia
  • Research Site
    Moscow, 141371, Russia
  • Research Site
    Saint Petersburg, 188820, Russia
  • Research Site
    Saint Petersburg, 190005, Russia
  • Research Site
    Saint Petersburg, 192019, Russia
  • Research Site
    Saint Petersburg, 197341, Russia
  • Research Site
    Saratov, 410028, Russia
  • Research Site
    Saratov, 410060, Russia
  • Research Site
    Stavropol, 357034, Russia
  • Research Site
    Tomsk, 634014, Russia
  • Research Site
    Belgrade, 11000, Serbia
  • Research Site
    Kovin, 26220, Serbia
  • Research Site
    Kragujevac, 34000, Serbia
  • Research Site
    Niš, 18000, Serbia
  • Research Site
    Novi Kneževac, 23330, Serbia
  • Research Site
    Vršac, 26300, Serbia
  • Research Site
    Kharkiv, 61068, Ukraine
  • Research Site
    Kherson, 73488, Ukraine
  • Research Site
    Kyiv, 01030, Ukraine
  • Research Site
    Kyiv, 01133, Ukraine
  • Research Site
    Kyiv, 08631, Ukraine
  • Research Site
    Lviv, 79021, Ukraine
  • Research Site
    Vinnytsia, 21005, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Jun 2023, 44 months.

Results were first posted in Jun 2026, 3 years after primary completion. A results delay was requested in May 2024.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 44 months is above that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2019
First posted
Sep 17, 2019
StartActual
Oct 14, 2019
Primary completionActual
Jun 14, 2023
CompletionActual
Jun 14, 2023
Results delay requested
May 28, 2024
Results first posted
Jun 18, 2026
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04092686
Responsible party
Sponsor
First posted
Sep 17, 2019
Start date
Oct 14, 2019
Primary completion
Jun 14, 2023
Completion
Jun 14, 2023
Results posted
Jun 18, 2026
Last update
Jun 18, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SEP-363856

Start the discussion